Anavex Life Sciences (AVXL) Current Deferred Revenue (2015 - 2025)
Anavex Life Sciences recorded quarterly Current Deferred Revenue of $805000.0 in Q2 2025, down 2.9% quarter-over-quarter from $829000.0 in Q1 2025, and down 12.21% year-over-year from $917000.0 in Q2 2024.
Anavex Life Sciences' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $805000.0 for Q2 2025.
- In Q2 2025, Current Deferred Revenue fell 12.21% year-over-year to $805000.0; the TTM figure through Jun 2025 stood at $805000.0 (down 12.21% YoY), while the FY2024 annual figure was $842000.0, down 8.18% from the prior year.
- Current Deferred Revenue came in at $805000.0 for Q2 2025 at Anavex Life Sciences, down from $829000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $917000.0 in Q3 2023 to a low of $443831.0 in Q2 2021.
- A 5-year average of $715188.1 and a median of $829000.0 in 2024 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue jumped 106.61% in 2023 and declined 12.21% in 2025, its largest moves.
- Anavex Life Sciences' Current Deferred Revenue stood at $443831.0 in 2021, then jumped by 106.56% to $916763.0 in 2022, then climbed by 0.03% to $917000.0 in 2023, then slipped by 9.6% to $829000.0 in 2024, then declined by 2.9% to $805000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $805000.0, $829000.0, and $829000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 829,000.00 |
| Dec 31, 2024 | 829,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Jun 30, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Dec 31, 2023 | 917,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 916,763.00 |
| Mar 31, 2023 | 916,763.00 |
| Dec 31, 2022 | 916,763.00 |
| Sep 30, 2022 | 443,831.00 |
| Jun 30, 2022 | 443,831.00 |
| Mar 31, 2022 | 443,831.00 |
| Dec 31, 2021 | 443,831.00 |
| Sep 30, 2021 | 443,831.00 |
| Jun 30, 2021 | 443,831.00 |
| Mar 31, 2021 | 487,111.00 |
| Jun 30, 2017 | 19,073.00 |
| Mar 31, 2017 | 86,205.00 |
| Dec 31, 2016 | 31,481.00 |
| Sep 30, 2016 | 70,532.00 |
| Jun 30, 2016 | 27,124.00 |
| Mar 31, 2016 | 5,445.00 |
| Dec 31, 2015 | 32,559.00 |
| Sep 30, 2015 | 71,614.00 |